Guy Sauvageau

USPTO Granted Patents = 12 (Patent Applications = 8)

CIPO Patents = 4 (Patent Applications = 7)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 25(Granted Patents)

Location History:

Montreal, CA (2008 - 2023)
Montréal, CA (2016 - 2024)

Company Filing History:

10 out of 183

Universitéde Montreal

patents

2 out of 14

Rsem, Limited Partnership

patents

2 out of 61

British Columbia Cancer Agency Branch

patents

4. 1 out of 1

Institut De Recherche Cliniques De Montréal

patent

5. 1 out of 6

Adaerata, Limited Partnership

patents

6. 1 out of 43

Valorisation-recherche, Limited Partnership

patents

7. 1 out of 289

Fred Hutchinson Cancer Center

patents

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12286426 - Heterocyclic mitochondrial activity inhibitors and uses thereof (2025-04-29),

2. 12011460 - Expansion of NK and DC cells in vivo mediating immune response (2024-06-18),

3. 11760754 - Heterocyclic mitochondrial activity inhibitors and uses thereof (2023-09-19),

4. 11725187 - Selection of human hematopoetic stem cells using EPCR (2023-08-15),

5. 11696928 - Compounds and use thereof in the expansion of stem cells and/or progenitor cells (2023-07-11),

6. 10647718 - Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells (2020-05-12),

7. 10336747 - Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells (2019-07-02),

8. 10273503 - Compounds and methods for enhancing viral gene transfer to human hematopoietic cells (2019-04-30),

9. 9757378 - Methods to modulate acute myeloid leukemia stem/progenitor cell expansion and/or differentiation (2017-09-12),

10. 9409906 - Pyrimido[4,5-B]indole derivatives and use thereof in the expansion of hematopoietic stem cells (2016-08-09),

11. 8039436 - Mutated HOXB4 proteins with improved stability, and methods of use thereof (2011-10-18),

12. 7358045 - Methods for determining a predisposition to develop breast adenocarcinoma or breast inflammatory carcinoma (2008-04-15),

As you are interested in inventor Guy Sauvageau, let's delve into his impressive profile.

Title: Unraveling the Innovative Mind of Guy Sauvageau

Introduction:

Guy Sauvageau, a prominent inventor hailing from the vibrant city of Montréal, CA, has left an indelible mark in the field of medical research and innovation. With a stellar track record, Sauvageau has garnered recognition for his groundbreaking work in cancer treatment and stem cell transplantation.

Latest Patents:

Sauvageau's latest patents showcase his ingenuity in developing novel therapeutic approaches. One of his recent inventions includes "Heterocyclic mitochondrial activity inhibitors and uses thereof", aimed at treating cancers sensitive to mitochondrial activity inhibition. Another noteworthy patent is the method for selecting human hematopoietic stem cells using EPCR, which holds great promise for stem cell transplantation procedures.

Career Highlights:

During his illustrious career, Guy Sauvageau has been affiliated with esteemed institutions such as the Université de Montréal. His contributions to the research community have significantly advanced the understanding and treatment of diseases, particularly in the realm of cancer biology and hematopoietic stem cell research.

Collaborations:

Sauvageau's collaborative spirit is evident through his work with accomplished colleagues like Yves Gareau and Iman Fares. Together, they have synergized their expertise to drive innovation and push the boundaries of scientific discovery.

Conclusion:

In conclusion, Guy Sauvageau's relentless pursuit of innovation and commitment to scientific excellence continue to inspire and shape the landscape of medical research. His visionary approach and transformative inventions have paved the way for new avenues in cancer therapy and stem cell biology, leaving a lasting legacy in the realm of scientific innovation.

This text is generated by artificial intelligence and may not be accurate.